Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD

World News: . []

This randomized multicentre controlled parallel-group Phase 3 study France Belgium LINK  100 adult patients with grade II-IV SR-aGvHD LINK  with inolimomab versus control ATG anti-thymocyte LINK  approved in this indication in France only) ...

More news and information about Elsalys Biotech

Published By:

Globe Newswire: 09:00 GMT Wednesday 23rd January 2019

Published: .

Search for other references to "long" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us